Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

NCT06401330 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT06401330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06401330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Recruiting
Start date
April 15, 2025
Completion date
February 13, 2031
Enrollment
1,656 (estimated)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

stage i mixed cell type kidney wilms tumor, stage ii mixed cell type kidney wilms tumor, stage iii mixed cell type kidney wilms tumor, stage iv mixed cell type kidney wilms tumor